| Species Reactivity | Human; Cynomolgus |
| Clone | Clone A |
| Source/Isotype | Human IgG1, Kappa |
| Application | Bioactivity-ELISA |
| Target | Detects TREM1 |
| Gene | TREM1 |
| Other Names | CD354, TREM-1 |
| Gene ID | 54210 (Human);102129811 (Cynomolgus) |
| Background | Targeting TREM1 (Triggering Receptor Expressed on Myeloid cells 1) with specific antibodies holds significant therapeutic promise. TREM1 is a key amplifier of innate immune responses, and its overactivation drives pathological inflammation in sepsis, ischemic stroke, inflammatory bowel disease, and COVID-19. Anti-TREM1 antibodies can selectively block this amplification loop without completely abolishing host defense, offering a safer immunomodulatory strategy than broad anti-inflammatory agents. Emerging evidence also implicates TREM1 in tumor immune evasion and fibrosis, expanding potential applications to oncology and chronic organ diseases. Thus, developing anti-TREM1 biologics represents a valuable approach for “resetting” dysregulated inflammation across diverse conditions. |
| Storage | Store at 2-8℃ short term (1-2 weeks). Store at ≤ -20℃ long term. Avoid repeated freeze-thaw. |
| Formulation | Supplied as a 0.2 μm filtered solution of PBS, pH7.2-7.4. |
| Endotoxin | < 1 EU/mg, determined by LAL gel clotting assay |
| Species Reactivity | Human; Cynomolgus |
| Clone | Clone A |
| Source/Isotype | Human IgG1, Kappa |
| Application | Bioactivity-ELISA |
| Target | Detects TREM1 |
| Gene | TREM1 |
| Other Names | CD354, TREM-1 |
| Gene ID | 54210 (Human);102129811 (Cynomolgus) |
| Background | Targeting TREM1 (Triggering Receptor Expressed on Myeloid cells 1) with specific antibodies holds significant therapeutic promise. TREM1 is a key amplifier of innate immune responses, and its overactivation drives pathological inflammation in sepsis, ischemic stroke, inflammatory bowel disease, and COVID-19. Anti-TREM1 antibodies can selectively block this amplification loop without completely abolishing host defense, offering a safer immunomodulatory strategy than broad anti-inflammatory agents. Emerging evidence also implicates TREM1 in tumor immune evasion and fibrosis, expanding potential applications to oncology and chronic organ diseases. Thus, developing anti-TREM1 biologics represents a valuable approach for “resetting” dysregulated inflammation across diverse conditions. |
| Storage | Store at 2-8℃ short term (1-2 weeks). Store at ≤ -20℃ long term. Avoid repeated freeze-thaw. |
| Formulation | Supplied as a 0.2 μm filtered solution of PBS, pH7.2-7.4. |
| Endotoxin | < 1 EU/mg, determined by LAL gel clotting assay |
